DSMB Approves Clearmind Medicine's CMND-100 AUD Trial to Advance to Next Stage with Higher Dose
CMND sits 15% above its 52-week low of $1.05 on light trading volume (0.1× avg).
Summary
Clearmind Medicine announced that its independent Data and Safety Monitoring Board (DSMB) has approved the continuation of its Phase I/IIa clinical trial for CMND-100 in Alcohol Use Disorder, based on positive safety results from the second cohort.
Key Events · Product Development and Regulatory · CMND
-
DSMB Approval for Trial Progression
The independent Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the Phase I/IIa clinical trial for CMND-100 in Alcohol Use Disorder.
-
Positive Safety Profile
The approval was based on additional topline positive safety results from the second cohort, reinforcing a favorable safety and tolerability profile with no serious adverse events.
-
Advancement to Higher Dose Cohort
The trial will now advance to the third cohort, where participants will receive a double dose (80 mg) of CMND-100 compared to the second cohort.
Analysis · CMND · Life Sciences
This 6-K reports a significant positive development for Clearmind Medicine, a clinical-stage biotech company. The unanimous approval from the independent Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa trial for CMND-100 in Alcohol Use Disorder, based on positive safety and tolerability data from the second cohort, de-risks the program. The decision to advance to a higher dose in the third cohort indicates strong confidence in the drug's safety profile, which is crucial for a company with a small market capitalization. This progress is a key milestone that could positively impact investor sentiment and the company's long-term prospects.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.9% of the 961 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $1.05 to $52.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.